CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS

Lobbying for NOVARTIS · Bio-pharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 16, 2026

Bills named in this filing 1

Lobbying activity 2

Health Issues

Support for: H.R. 1672 - Maintaining Investments in New Innovation Act (MINI Act)

Medicare/Medicaid

Issues related to the pharmaceutical industry

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.